Report : North America Gastroparesis Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Idiopathic, Diabetic, Post-Surgical, and Others), Drug Class (Prokinetic Agents, Botulinum Toxin Injections, and Antiemetic Agents), and Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others)
Idiopathic Segment to Dominate North America Gastroparesis Market during 2019–2027
According to a new market research study on “North America Gastroparesis Market to 2027 – COVID-19 Impact and Regional Analysis and Forecast by Type, Drug Class, and Distribution Channel” is expected to reach US$ 2,032.27 million by 2027 from 1,488.03 US$ million in 2020. The market is estimated to grow at a CAGR of 4.6% from 2020 to 2027. The report provides trends prevailing in the North America gastroparesis market along with the drivers and restraints pertaining to the market growth. Growing diabetes mellitus prevalence is the major factor driving the growth of the North America gastroparesis market. However, issues associated with side effects of gastroparesis drugs hinders the growth of North America gastroparesis market.
The North America gastroparesis market is segmented on the basis of type, drug class, distribution channel, and country. The North America gastroparesis market, by type, is segmented into idiopathic, diabetic, post-surgical, and others. The idiopathic segment held the largest share of the market in 2019. The North America gastroparesis market, by drug class type, is segmented into prokinetic agents, botulinum toxin injection, and antiemetic agents. The prokinetic agents segment held the largest share of the market in 2019. Based on distribution channel, the North America gastroparesis market is segmented into retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019. Based on country, the North America gastroparesis market is segmented into US, Canada, and Mexico. US held the largest market share in 2019.
Although the healthcare sector had witnessed SARS, H1N1, and other outbreaks in the last few years, the severity of the COVID-19 has made the situation more complicated due to its mode of transmission. North America has been witnessing a growing number of COVID-19 cases since its outbreak. In patients with chronic GI illnesses, COVID-19 may initially present as a flare of their underlying GI conditions as viruses have historically been implicated in exacerbations of GI disorders, including gastroparesis. Moreover, according to the world gastroenterology organization, there has been observed a rise in GI complications after COVID-19 symptoms. Patients with COVID-19 may complain of digestive symptoms such as poor appetite, nausea, vomiting, diarrhea, symptoms, or disease activity for pre-existing digestive diseases such as inflammatory bowel disease. However, according to a review of Diabetic Gastroparesis for the Community Pharmacist published in 2016, over 29.1 million people in the US have diabetes and have faced with the complications associated with the disease. Diabetes is the most common systemic disease that causes gastroparesis. Moreover, according to data published by National Center for Biotechnology Information (NCBI) in September 2020, nausea and vomiting from detailed consideration as symptoms of COVID?19 is surprising as it can be an early presenting symptom. Thus, there has been observed a rise in the sale of prokinetic agents and antiemetic agents. However, due to disruption in supply chain and governmental orders restricting certain activities in response to COVID-19, including changes in on-site operations to reduce manufacturing capacity and implement social distancing, reductions in suppliers’ ability to source, ship raw materials in alignment with demands, work stoppages, slowdowns, and delays, the market may show a slowdown.
Allergan Plc; ANI Pharmaceuticals, Inc.; Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.); Cinrx Pharma, LLC (Cindome Pharma); EVOKE PHARMA; Ipca Laboratories Ltd.; Johnson and Johnson Services, Inc.; NEUROGASTRX, INC.; Pfizer Inc.; and TEVA PHARMACEUTICAL INDUSTRIES LTD are among the leading companies in the North America gastroparesis market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, Evoke Pharma, Inc. has received U.S. Food and Drug Administration (FDA) the approval, and New Drug Application (NDA) for GIMOTI™ (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Contact Person: Sameer Joshi
Email Id: email@example.com